(Z)-3-(1-(1H-pyrrol-2-yl)ethylidene)-5-aminoindolin-2-one | 946843-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (Z)-3-(1-(1H-pyrrol-2-yl)ethylidene)-5-aminoindolin-2-one
• CAS: 946843-76-1
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: YZQHJYTWBNPFGI-JYRVWZFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.48
• 重原子数：
  18.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  70.91
• 氢给体数：
  3.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (Z)-3-(1-(1H-pyrrol-2-yl)ethylidene)-5-aminoindolin-2-one 、 三甲基硅基异氰酸酯 以 四氢呋喃 为溶剂， 以89%的产率得到BX-517
  参考文献：
  名称：

  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity

  摘要：

  HTS screening identified I with micromolar inhibitory activity against PDK1. Optimization of 1 afforded 4i (BX-517) which has single-digit nanomolar activity against PDK1 and excellent selectivity against PKA. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.071
• 作为产物：
  描述：

  5-硝基-1,3-二氢-2H-吲哚-2-酮 在 palladium on activated charcoal 哌啶 、 氢气 作用下， 以 甲醇 为溶剂， 130.0 ℃ 、275.8 kPa 条件下， 生成 (Z)-3-(1-(1H-pyrrol-2-yl)ethylidene)-5-aminoindolin-2-one
  参考文献：
  名称：

  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity

  摘要：

  HTS screening identified I with micromolar inhibitory activity against PDK1. Optimization of 1 afforded 4i (BX-517) which has single-digit nanomolar activity against PDK1 and excellent selectivity against PKA. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.071

文献信息

• Indolinone derivatives and their use in treating disease-states such as cancer
  申请人：Arnaiz Damian

  公开号：US20050090541A1

  公开（公告）日：2005-04-28

  Indolinone derivatives, such as compounds of the formula (I): wherein A, m, n, R 1 , R 2 , R 3 , R 5 and R 6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.

  Indolinone衍生物，例如公式（I）中的化合物：其中A，m，n，R1，R2，R3，R5和R6如本文所述，据本文披露，可用于治疗通过抑制PDK-1活性缓解疾病状态的哺乳动物。
• INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER
  申请人：Schering Aktiengesellschaft

  公开号：EP1680401A2

  公开（公告）日：2006-07-19
• US7105563B2
  申请人：——

  公开号：US7105563B2

  公开（公告）日：2006-09-12
• [EN] INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER<br/>[FR] DERIVES D'INDOLINONE ET UTILISATIONS DE CEUX-CI POUR TRAITER DES ETATS PATHOLOGIQUES TELS QUE LE CANCER
  申请人：SCHERING AG

  公开号：WO2005040116A2

  公开（公告）日：2005-05-06

  Indolinone derivatives, such as compounds of the formula (I); wherein A, m, n, R1, R 2 , R 3 , R 5 and R 6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.
• Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity
  作者：Imadul Islam、Judi Bryant、Yuo-Ling Chou、Monica J. Kochanny、Wheeseong Lee、Gary B. Phillips、Hongyi Yu、Marc Adler、Marc Whitlow、Elena Ho、Dao Lentz、Mark A. Polokoff、Babu Subramanyam、James M. Wu、Daguang Zhu、Richard I. Feldman、Damian O. Arnaiz

  DOI：10.1016/j.bmcl.2007.04.071

  日期：2007.7

  HTS screening identified I with micromolar inhibitory activity against PDK1. Optimization of 1 afforded 4i (BX-517) which has single-digit nanomolar activity against PDK1 and excellent selectivity against PKA. (C) 2007 Elsevier Ltd. All rights reserved.